A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined how a high-fat diet (HFD) alters the gut microbiota to promote cancer progression. The researchers focused on whether HFD-associated gut bacteria drive the generation of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), an immune cell population linked to tumor immune evasion. They investigated the mechanism connecting microbial metabolism, specifically leucine production, to mTORC1 signaling and myeloid cell differentiation. The work combined mouse modeling with clinical correlation in breast cancer patients.
Who was studied?
The study used tumor-bearing mice across several experimental models, including HFD feeding, fecal microbiota transplantation, antibiotic treatment, and direct bacterial gavage. Clinically, the researchers also studied female patients with breast cancer, examining associations between obesity, obesity-related gut microbiota, peripheral blood leucine levels, and clinical outcomes. Exact sample sizes for the human cohort are not stated in the abstract.
What were the most important findings?
Obesity and obesity-related gut microbiota were associated with poor prognosis and more advanced clinicopathological status in female breast cancer patients. In mice, HFD-related gut microbiota promoted cancer progression by generating PMN-MDSCs. Mechanistically, the HFD microbiota released abundant leucine, which activated the mTORC1 signaling pathway in myeloid progenitors to drive PMN-MDSC differentiation. Elevated peripheral blood leucine linked to the HFD microbiota correlated with greater tumoral PMN-MDSC infiltration and worse clinical outcomes in patients.
What are the greatest implications of this study?
The findings define a gut-bone marrow-tumor axis through which diet-altered microbiota can reprogram myeloid cell fate and suppress anti-tumor immunity. Targeting microbial leucine production or the mTORC1 pathway in myeloid progenitors could represent a new strategy to limit PMN-MDSC-driven immune suppression. This work also strengthens the rationale for dietary and microbiota-directed interventions as adjuncts in breast cancer management. Further research is needed to confirm these mechanisms and their clinical relevance in larger patient cohorts.